Silvia Brugiapaglia
Overview
Explore the profile of Silvia Brugiapaglia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brugiapaglia S, Spagnolo F, Intonti S, Novelli F, Curcio C
Cells
. 2024 Sep;
13(18.
PMID: 39329742
Pancreatic adenocarcinoma (PDA) represents the fourth leading cause of cancer-related mortality in the USA. Only 20% of patients present surgically resectable and potentially curable tumors at diagnosis, while 80% are...
2.
Brugiapaglia S, Bulfamante S, Curcio C, Arigoni M, Calogero R, Bonello L, et al.
Front Immunol
. 2024 Aug;
15:1427424.
PMID: 39176093
Introduction: Pancreatic Ductal Adenocarcinoma (PDA) is one of the most aggressive malignancies with a 5-year survival rate of 13%. Less than 20% of patients have a resectable tumor at diagnosis...
3.
Curcio C, Mucciolo G, Roux C, Brugiapaglia S, Scagliotti A, Guadagnin G, et al.
J Exp Clin Cancer Res
. 2024 Jun;
43(1):157.
PMID: 38824552
Phosphoinositide-3-kinase γ (PI3Kγ) plays a critical role in pancreatic ductal adenocarcinoma (PDA) by driving the recruitment of myeloid-derived suppressor cells (MDSC) into tumor tissues, leading to tumor growth and metastasis....
4.
Caronni N, La Terza F, Vittoria F, Barbiera G, Mezzanzanica L, Cuzzola V, et al.
Nature
. 2023 Nov;
623(7986):415-422.
PMID: 37914939
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with high resistance to therapies. Inflammatory and immunomodulatory signals co-exist in the pancreatic tumour microenvironment, leading to dysregulated repair and cytotoxic responses....
5.
Curcio C, Rosso T, Brugiapaglia S, Guadagnin G, Giordano D, Castellino B, et al.
Clin Exp Med
. 2023 Nov;
23(8):5089-5100.
PMID: 37910256
Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis due to a lack of early diagnostic markers and effective therapy. In PDA patients, the glycolytic enzyme and plasminogen receptor alpha-enolase (ENO1)...
6.
Farias T, Brugiapaglia S, Croci S, Magistroni P, Curcio C, Zguro K, et al.
HLA
. 2023 Oct;
103(1):e15251.
PMID: 37850268
Extreme polymorphism of HLA and killer-cell immunoglobulin-like receptors (KIR) differentiates immune responses across individuals. Additional to T cell receptor interactions, subsets of HLA class I act as ligands for inhibitory...
7.
Mucciolo G, Roux C, Scagliotti A, Brugiapaglia S, Novelli F, Cappello P
Cancer Drug Resist
. 2022 May;
3(3):491-520.
PMID: 35582441
Since the journal deemed cancer immunotherapy as the "breakthrough of the year" in 2014, there has been an explosion of clinical trials involving immunotherapeutic approaches that, in the last decade...
8.
Curcio C, Brugiapaglia S, Bulfamante S, Follia L, Cappello P, Novelli F
Molecules
. 2021 Apr;
26(6).
PMID: 33804240
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal forms of human cancer, characterized by unrestrained progression, invasiveness and treatment resistance. To date, there are limited curative options, with...